Healthcare Global Enterprises Ltd Share Price – NSE  / BSE

Healthcare, Small Cap

Total operating expenditure for the period under review was Rs 559.16 crore, up 16.6% YoY.

The company recorded an exceptional charge of Rs 31.91 crore in the March 2026 quarter.

HealthCare Global stated that during the quarter and year ended 31 March 2026, the management committed to a plan to divest the company's entire equity interest in BACC Healthcare (BACC), a wholly owned subsidiary engaged in the management of infertility treatment hospitals.

Pursuant to the investor outreach process, non-binding offers were received from potential investors. Accordingly, the assets and liabilities of BACC have been classified as a disposal group held for sale as at 31 March 2026.

Along with the classification as held for sale, the carrying amount of goodwill allocated to the cash-generating unjt (i.e., BACC) was assessed for impainnent and an impairment loss of Rs 31.91 crore has been recognised as an exceptional item for the quarter and year ended 31 March 2026 based on the net fair value of the consideration receivable.

Accordingly, profit before tax in Q4 FY26 stood at Rs 1.25 crore in Q4 FY26, down by 90.8% from Rs 13.62 crore in Q4 FY25.

For FY26, the company has recorded consolidated net profit and revenue from operations of Rs 13.76 crore (down 69% YoY) and Rs 2,538.43 crore (up 14.4% YoY), respectively.

HealthCare Global Enterprises (HCG) is India?s largest dedicated cancer hospital network, operating 25 hospitals across India and Africa. HCG?s comprehensive cancer centers provide expertise and advanced technologies for the effective diagnosis and treatment of cancer under one roof. Under 'Milann', HCG operates fertility centers as well.

The scrip rose 1.58% to currently trade at Rs 656.90 on the BSE.

Powered by Capital Market - Live News

Net profit of Healthcare Global Enterprises declined 70.52% to Rs 2.17 crore in the quarter ended March 2026 as against Rs 7.36 crore during the previous quarter ended March 2025. Sales rose 11.46% to Rs 650.29 crore in the quarter ended March 2026 as against Rs 583.43 crore during the previous quarter ended March 2025.

For the full year,net profit declined 69.02% to Rs 13.76 crore in the year ended March 2026 as against Rs 44.41 crore during the previous year ended March 2025. Sales rose 14.44% to Rs 2538.43 crore in the year ended March 2026 as against Rs 2218.14 crore during the previous year ended March 2025.

Powered by Capital Market - Live News

Healthcare Global Enterprises has today launched its new comprehensive cancer hospital in Hebbal with up to 132 beds, strengthening access to advanced oncology care in North Bengaluru (HCG Cancer Hospital, Hebbal). The new facility marks a major advancement in the region's oncology landscape, bringing together clinical excellence, compassionate care and advanced technology to make world-class cancer treatment more accessible to people across Karnataka.

Marking a significant milestone in precision oncology, the new facility introduces Karnataka's first Elekta Unity MR-Linac, one of the world's most advanced precision radiation therapy platforms. The technology combines high-quality MRI imaging with a linear accelerator to enable highly precise, adaptive cancer treatment. Designed as a full-spectrum oncology centre, the hospital brings together diagnosis, treatment, recovery support, and patient-centric care under one roof, making world-class cancer care more accessible to patients across North Bengaluru.

Healthcare Global Enterprises will hold a meeting of the Board of Directors of the Company on 19 May 2026.